Latest Regulatory News

ReNerve Limited has secured market approval for its NervAlign® Nerve Cuff in Malaysia, marking a key milestone in its Asia-Pacific expansion strategy. This approval follows earlier clearances in Hong Kong and Thailand, positioning the company to tap into a growing regional nerve repair market.

Southern Cross Gold Consolidated Ltd. has achieved a pivotal regulatory milestone enabling underground exploration at its Sunday Creek project, backed by strong drilling results and a robust cash position of $130.4 million.

BlackRock Investment Management (Australia) Limited has announced the Distribution Reinvestment Plan (DRP) prices for several Australian-domiciled iShares ETFs for the December 2025 distribution period, providing key details for investors opting into reinvestment.

Metgasco shareholders have approved the sale of their 25% stake in the Southern Flank joint ventures to Vintage Energy, marking a key milestone in Vintage’s strategic expansion. The deal still awaits final conditions before completion.

Neuren Pharmaceuticals’ partner Acadia projects DAYBUE sales to reach around US$700 million by 2028, driven by US market expansion and international approvals. The launch of a new formulation and ongoing clinical trials in Japan underpin this optimistic outlook.

betr Entertainment has reported a robust 24.5% increase in turnover for Q2 FY26 alongside a strategic on-market share buy-back of up to 10%, signalling confidence in its intrinsic value and growth prospects.

Little Green Pharma Ltd has agreed to acquire Cannatrek Ltd in a transformational merger that will create a leading vertically integrated medicinal cannabis group across Australia and Europe. The deal combines cultivation, manufacturing, distribution, clinics, and digital health platforms under one roof, positioning the combined entity for accelerated growth.

Stavely Minerals has initiated an updated 2026 Scoping Study for its copper-gold project in Western Victoria, driven by significantly higher metal prices and improved economic prospects since 2022.

Magnum Mining and Exploration Limited has launched a $7 million capital raising via a placement of shares accompanied by 630 million new options exercisable at $0.015, set to expire in three years. The offer aims to bolster working capital and advance exploration projects across the US and Brazil.

Argent BioPharma has signed a binding agreement to acquire AusCann’s 48% stake in CannPal, enhancing its clinical and intellectual property assets for CannEpil®. The deal includes an option for the Neuvis® drug-delivery platform and aligns with Argent’s U.S. dual-listing ambitions.

Predictive Discovery has secured a crucial court approval for its acquisition of Robex Resources, paving the way for the deal to close in early 2026 pending final regulatory consents.

Racura Oncology has launched a strategic collaboration with Emory University to investigate (E,E)-bisantrene’s potential to overcome resistance to osimertinib in EGFR-mutated non-small cell lung cancer. This partnership aims to bolster Racura’s HARNESS-1 clinical trial and strengthen its position in the competitive lung cancer treatment landscape.